Winship Cancer Institute of Emory University | Strategic Alliance Partners

March 23, 2023

Kevin Kalinsky, MD, MS, discusses genetic sequencing in triple-negative breast cancer, the significance of breast cancer tumor board discussions for informing further research and optimizing patient care, and how future directions in breast cancer treatment are building off the current benefits of drugs classes like antibody-drug conjugates.

March 13, 2023

Closing out their discussion on biomarkers and precision medicine in cancer care, key opinion leaders look toward future evolutions in the oncology landscape.

March 13, 2023

Ryan Haumschild, PharmD, MS, MBA, reflects on how oncologic pharmacists can help to develop treatment pathways and educate patients on precision medicine.

March 06, 2023

Expert perspectives on the role of an oncologic pharmacist within a tumor board and how they can improve upon precision medicine in cancer management.

March 06, 2023

Comprehensive discussion on the role of tumor boards—or more specifically, molecular tumor boards—in the optimal management of patients with cancer.

February 27, 2023

Kathryn Maples, PharmD, BCOP, discusses recent approvals, updated labeling, and drug removals across leukemia, lymphoma, and multiple myeloma.

February 27, 2023

Key opinion leaders in the field of cancer management discuss resistance to the uptake of biomarker testing and precision medicine, with deference to the community setting.

February 27, 2023

Expert pathologist Samuel K. Caughron, MD, FCAP, shares best strategies for the timing and utilization of biomarker testing while managing patients with cancer.

February 20, 2023

Timothy J. Pluard, MD; Ossama Tawfik, MD; and Sujith R. Kalmadi, MD, reflect on how they update their biomarker testing strategies as the field of cancer care and precision medicine evolves.

February 20, 2023

Expert perspectives on the wide array of biomarker testing modalities available to patients receiving treatment for cancer.

February 13, 2023

Comprehensive discussion on how best to interpret and document results from biomarker testing, along with considerations for communicating results with other healthcare professionals.

February 13, 2023

Key opinion leaders highlight challenges to adequate biomarker testing in cancer care and consider the value of collaboration to overcome these barriers.

February 02, 2023

For Kevin Kalinsky, MD, MS, director of breast medical oncology at the Winship Cancer Institute of Emory University in Atlanta, Georgia, his work on the RxPONDER trial serves as one of a few accomplishments for which he is grateful that have impacted clinical care.

January 04, 2023

Jane L. Meisel, MD, discusses the effect of the HER2-low classification for patients with breast cancer.

December 15, 2022

Suchita Pakkala, MD, discusses ongoing efforts to integrate local therapy into HER2-positive breast cancer treatment.

December 08, 2022

Jason Romancik, MD, discusses efforts to maximize the efficacy of CAR T-cell therapy in non-Hodgkin lymphoma.

November 17, 2022

Jason Romancik, MD, discusses the benefit of axicabtagene ciloleucel vs standard of care as a second-line treatment for patients with relapsed/refractory diffuse large B-cell lymphoma.

November 09, 2022

Nabil F. Saba, MD, FACP, expanded on efficacy data from a phase 2 trial investigating pembrolizumab plus cabozantinib in patients with recurrent metastatic head and neck squamous cell carcinoma and current challenges and safety concerns in selecting patients for evaluation.

November 08, 2022

A doublet regimen comprised of pembrolizumab and cabozantinib elicited encouraging responses in patients with recurrent metastatic head and neck squamous cell carcinoma, meeting the primary end point of a phase 2 trial.

November 02, 2022

Nabil Saba, MD, FACP, discusses the evaluation of pembrolizumab plus cabozantinib in patients with recurrent metastatic head and neck squamous cell carcinoma.